Short answer
CareDx, Inc. (CDNA) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CareDx announced financial results for the quarter ended June 30, 2026.
CareDx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- CareDx announced financial results for the quarter ended June 30, 2026
- Full results and management commentary appear in Exhibit 99.1, the accompanying press release
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation current as of June 30, 2026
- Investor-relevant business information available on CareDx’s website
- No ongoing obligation to update the presentation disclosed
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $132M, up 52% YoY, with Testing Services revenue up 61% to $100M
- Adjusted EBITDA $25M, up from $5M, with margin reaching 19% from 6%
- 2026 revenue guidance raised to $490M-$500M from $447M-$465M
- 2026 adjusted EBITDA guidance raised to $66M-$78M from $43M-$57M
- $113M Lab Products sale gain drove GAAP net income of $111M, while non-GAAP net income was $20M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CareDx, Inc. 8-K filings
Get the next CDNA 8-K as it lands
Follow CDNA for push alerts, or ask the research agent what this filing means.